NCT03816878View on ClinicalTrials.gov

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 8, 2019

Primary Completion Date

April 18, 2019

Study Completion Date

March 17, 2020

Conditions
Influenza
Interventions
BIOLOGICAL

H5N1 pISV

Administered as an intramuscular (IM) injection

Trial Locations (1)

21205

Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03816878 - Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals | Biotech Hunter | Biotech Hunter